Sun L, Brentnall A, Patel S, et al. - Researchers investigated the cost-effectiveness of multigene testing of all patients with breast cancer (BC) vs the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria. In the United Kingdom and US populations, comparison of lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC vs BRCA1/BRCA2 testing based on FH or clinical criteria was done. Assessment of data from 11,836 women was performed; unselected BRCA1/BRCA2/PALB2 testing at breast cancer diagnosis was identified to be remarkably cost-effective compared with BRCA1/BRCA2 testing based on clinical criteria or family history. Incremental cost-effectiveness ratios were £10,464 or £7,216 and $65,661 or $61,618 per quality-adjusted life-year for UK and US health systems, respectively. As per estimates, 2,101 cases of breast or ovarian cancer and 633 deaths in the United Kingdom and 9,733 cases and 2,406 deaths in the United States could be prevented with undertaking one year’s unselected panel genetic testing. Findings thereby support modifying current policy to extend genetic testing to all women with breast cancer.